News

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem.

The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include:

  • A new name that reflects the commitment of Roanoke Blacksburg Innovation Alliance to elevating the local tech economy through vision, strategy, and collaboration.
  • A dynamic and modern logo that represents all four Alliance teams and evokes the momentum and creativity inherent in the regional innovation ecosystem.
  • Energetic brand colors that align across RBIA member companies.
  • A modern, user-friendly website designed to support existing innovation ecosystem members and attract new stakeholders.
“The new brand visually embodies the interconnected efforts of the Alliance and our collective vision to elevate the Roanoke Region and New River Valley as a nationally recognized hub for technology and biotechnology,” said RBIA CEO Erin Burcham.
The Alliance has accelerated 60+ tech companies and seen 850 high-paying jobs created in the region since 2017 and has been instrumental in crafting a creative culture that has seen 3,200+ patents filed since 2014. Further, through RBTC, the Alliance brings together 225 RBTC member companies for professional development, networking and talent retention.

Most recently, RBIA led a coalition to include 38 regional organizations, including Virginia Tech, Carilion, Virginia Western Community College, Blue Ridge Partnership for Health Science Careers and many others, to secure $4.9 million through GO Virginia’s Project VITAL. The funds will be used to further biotech and life science commercialization and establish Roanoke Blacksburg as a biomedical hub. The coalition aims to create 1,100 jobs over five years with a $40 million economic impact.

Roanoke Blacksburg Innovation Alliance unites a portfolio of organizations including Regional Accelerator and Mentoring Program (RAMP), Roanoke Blacksburg Technology Council (RBTC), and Common Wealth Angels all dedicated to tech-based economic advancement in the Roanoke Blacksburg region. Together, they form a full-stack network of support designed to accelerate innovation in the technology and life science industries and develop the Roanoke Blacksburg region into a nationally recognized hub for technology and biotechnology.

“The rebrand of the Roanoke Blacksburg Innovation Alliance honors the dedication of past leaders and the contributions of many collaborators in building a strong foundation for innovation in our region. It also sets a bold vision for the ambitious goals we will achieve together in the future,” Burcham said.

To experience the new look of Roanoke Blacksburg Innovation Alliance, visit rbia.tech.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like